Literature DB >> 20372802

PNUTS knockdown potentiates the apoptotic effect of Roscovitine in breast and colon cancer cells.

Gabriel De Leon1, Margaret Cavino, Mikilyn D'Angelo, Nancy A Krucher.   

Abstract

The phosphorylation state of Retinoblastoma protein (Rb) plays a role in cell proliferation and apoptosis. Within cells, cyclin dependent kinases (cdks) phosphorylate Rb in response to growth stimulatory signals, whereas protein phosphatase 1 (PP1) dephosphorylates Rb when cells stop proliferating or undergo apoptosis in response to anti-proliferative or stress signals. Stimulation of PP1 activity via siRNA mediated knockdown of its interacting protein PNUTS (Phosphatase Nuclear Targeting Subunit) leads to Rb dephosphorylation and apoptosis in cancer cells. We utilized two separate methods to modulate the phosphorylation state of Rb in cancer cells. Kinase activity toward Rb is inhibited by the clinically relevant cdk inhibitor, Roscovitine. In addition, siRNA mediated PNUTS knockdown stimulates phosphatase activity toward Rb. Either of these treatments in cancer cells causes a 2-fold stimulation of apoptosis. When activation of phosphatase activity is combined with inhibition of cdk activity toward Rb, however, cells exhibit a 4-fold increase in apoptosis. The mechanism by which PNUTS knockdown mediated PP1 activation leads to apoptosis was determined to be dependent on the activity of the transcription factor E2F1. The Rb phosphorylation profiles resulting from each treatment were analyzed and found to be similar but not identical. In addition, the two treatments differentially effect the expression of bcl-2 family proteins. Thus inhibition of cdk activity and activation of PP1 activity toward pRb are functionally distinct processes that together increase the apoptotic effect in cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20372802      PMCID: PMC3589106          DOI: 10.3892/ijo_00000611

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  46 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  PUMA induces the rapid apoptosis of colorectal cancer cells.

Authors:  J Yu; L Zhang; P M Hwang; K W Kinzler; B Vogelstein
Journal:  Mol Cell       Date:  2001-03       Impact factor: 17.970

3.  E2F4 deficiency promotes drug-induced apoptosis.

Authors:  Yihong Ma; Scott N Freeman; W Douglas Cress
Journal:  Cancer Biol Ther       Date:  2004-12-14       Impact factor: 4.742

4.  Dephosphorylation of Rb (Thr-821) in response to cell stress.

Authors:  Nancy A Krucher; Ethel Rubin; Vivienne C Tedesco; Michael H Roberts; Tara C Sherry; Gabriel De Leon
Journal:  Exp Cell Res       Date:  2006-05-10       Impact factor: 3.905

5.  Activation of p53 by roscovitine-mediated suppression of MDM2 expression.

Authors:  W Lu; L Chen; Y Peng; J Chen
Journal:  Oncogene       Date:  2001-05-31       Impact factor: 9.867

6.  RB-dependent S-phase response to DNA damage.

Authors:  K E Knudsen; D Booth; S Naderi; Z Sever-Chroneos; A F Fribourg; I C Hunton; J R Feramisco; J Y Wang; E S Knudsen
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

7.  Discovery and evaluation of dual CDK1 and CDK2 inhibitors.

Authors:  Marc Payton; Grace Chung; Peter Yakowec; Andrew Wong; Dave Powers; Ling Xiong; Nancy Zhang; Juan Leal; Tammy L Bush; Vincent Santora; Ben Askew; Andrew Tasker; Robert Radinsky; Richard Kendall; Steve Coats
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

Review 8.  The RB and p53 pathways in cancer.

Authors:  Charles J Sherr; Frank McCormick
Journal:  Cancer Cell       Date:  2002-08       Impact factor: 31.743

9.  Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine.

Authors:  Martina Paprskárová; Vladimír Krystof; Radek Jorda; Petr Dzubák; Marián Hajdúch; Józefa Wesierska-Gadek; Miroslav Strnad
Journal:  J Cell Biochem       Date:  2009-06-01       Impact factor: 4.429

Review 10.  Protein phosphatase 1--targeted in many directions.

Authors:  Patricia T W Cohen
Journal:  J Cell Sci       Date:  2002-01-15       Impact factor: 5.285

View more
  10 in total

Review 1.  Post-translational modifications on the retinoblastoma protein.

Authors:  Linbin Zhou; Danny Siu-Chun Ng; Jason C Yam; Li Jia Chen; Clement C Tham; Chi Pui Pang; Wai Kit Chu
Journal:  J Biomed Sci       Date:  2022-06-01       Impact factor: 12.771

Review 2.  A comprehensive review of the roles of E2F1 in colon cancer.

Authors:  Zejun Fang; Min Lin; Chunxiao Li; Hong Liu; Chaoju Gong
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

Review 3.  Therapeutic targeting of replicative immortality.

Authors:  Paul Yaswen; Karen L MacKenzie; W Nicol Keith; Patricia Hentosh; Francis Rodier; Jiyue Zhu; Gary L Firestone; Ander Matheu; Amancio Carnero; Alan Bilsland; Tabetha Sundin; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Bill Helferich; Chandra S Boosani; Gunjan Guha; Maria Rosa Ciriolo; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; Dipita Bhakta; Dorota Halicka; Elena Niccolai; Katia Aquilano; S Salman Ashraf; Somaira Nowsheen; Xujuan Yang
Journal:  Semin Cancer Biol       Date:  2015-04-11       Impact factor: 15.707

4.  PNUTS/PP1 regulates RNAPII-mediated gene expression and is necessary for developmental growth.

Authors:  Anita Ciurciu; Louise Duncalf; Vincent Jonchere; Nick Lansdale; Olga Vasieva; Peter Glenday; Andreii Rudenko; Emese Vissi; Neville Cobbe; Luke Alphey; Daimark Bennett
Journal:  PLoS Genet       Date:  2013-10-31       Impact factor: 5.917

5.  Dephosphorylation of the Retinoblastoma protein (Rb) inhibits cancer cell EMT via Zeb.

Authors:  Jacklynn V Egger; Maria V Lane; Lisa A Antonucci; Brixhilda Dedi; Nancy A Krucher
Journal:  Cancer Biol Ther       Date:  2016-09-19       Impact factor: 4.742

6.  Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.

Authors:  Sheelagh Frame; Chiara Saladino; Craig MacKay; Butrus Atrash; Peter Sheldrake; Edward McDonald; Paul A Clarke; Paul Workman; David Blake; Daniella Zheleva
Journal:  PLoS One       Date:  2020-07-09       Impact factor: 3.240

Review 7.  Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment.

Authors:  Oana-Maria Thoma; Markus F Neurath; Maximilian J Waldner
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

8.  Protein 4.1N acts as a potential tumor suppressor linking PP1 to JNK-c-Jun pathway regulation in NSCLC.

Authors:  Zi Wang; Bianyin Ma; Hui Li; Xiaojuan Xiao; Weihua Zhou; Feng Liu; Bin Zhang; Min Zhu; Qin Yang; Yayue Zeng; Yang Sun; Shuming Sun; Yanpeng Wang; Yibin Zhang; Haibo Weng; Lixiang Chen; Mao Ye; Xiuli An; Jing Liu
Journal:  Oncotarget       Date:  2016-01-05

9.  Phosphorylation of the Retinoblastoma protein (Rb) on serine-807 is required for association with Bax.

Authors:  Lisa A Antonucci; Jacklynn V Egger; Nancy A Krucher
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

10.  Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer.

Authors:  Andreas Marx; Andreas M Luebke; Till S Clauditz; Stefan Steurer; Christoph Fraune; Claudia Hube-Magg; Franziska Büscheck; Doris Höflmayer; Maria Christina Tsourlakis; Christina Möller-Koop; Ronald Simon; Guido Sauter; Cosima Göbel; Patrick Lebok; David Dum; Simon Kind; Sarah Minner; Jakob Izbicki; Thorsten Schlomm; Hartwig Huland; Hans Heinzer; Eike Burandt; Alexander Haese; Markus Graefen; Jan Meiners
Journal:  Dis Markers       Date:  2020-04-25       Impact factor: 3.434

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.